Patent Issues
The patents for the Rythmol family of products are owned by Reliant Pharmaceuticals, Inc., in Liberty Corner, N.J. Reliant acquired the patents from developer Abbott Laboratories, Inc., in 2003. Rythomol was originally developed in Europe and marketed by Knoll Pharma both in Europe and North America. The product was taken over by Abbott in 2001 when Abbott purchased Knoll.
Reliant Pharmaceuticals filed a federal patent infringement lawsuit against generic drug maker Par Pharmaceuticals, Inc., on December 19, 2006. The lawsuit, filed in the federal district court for Delaware, seeks to prevent Par from manufacturing a generic version of Rythmol. Par is seeking approval to do so from the U.S. Food and Drug Administration.
Reliant's patent for the drug was issued in October, 1997, and it expires in 2014. Par believes the patent is invalid, according to its filing with the FDA.
Read more about this topic: Propafenone
Famous quotes containing the words patent and/or issues:
“There is a patent office at the seat of government of the universe, whose managers are as much interested in the dispersion of seeds as anybody at Washington can be, and their operations are infinitely more extensive and regular.”
—Henry David Thoreau (1817–1862)
“Cynicism formulates issues clearly, but only to dismiss them.”
—Mason Cooley (b. 1927)